While the WT group showed remarkable reduction in tumor volume in response to erlotinib treatment and did not show regrowth after achieving near complete responses, the LATS1/2 KO group exhibited a significant but more limited tumor growth reduction during erlotinib treatment, and rapid regrowth after cessation of erlotinib administration (Fig. 7a(left), b). This evidence concerns the gene LATS1 and neoplasm.